Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339840 | 0.84 | BLM (0.58) | TAAR1RIPK1CYP1A2CYP2C19BLM | |
| SCHEMBL10680474 | 0.84 | BLM (0.58) | TAAR1RIPK1CYP1A2CYP2C19BLM | |
| SCHEMBL6339842 | 0.84 | BLM (0.58) | TAAR1RIPK1CYP1A2CYP2C19BLM | |
| SCHEMBL31563007 | 0.83 | GRM2 (0.58) | TAAR1GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL3616371 | 0.82 | GRM2 (0.51) | TAAR1GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL27748006 | 0.82 | GRM2 (0.51) | TAAR1GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL202819 | 0.82 | GRM2 (0.51) | TAAR1GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL10685677 | 0.82 | GRM2 (0.43) | GRM2GRM3CYP1A2CYP2C19BLM | |
| Hydrochloric Acid SCHEMBL1807415 | 0.80 | GRM2 (0.50) | TAAR1GRM2GRM3CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL31587976 | 0.80 | GRM2 (0.50) | TAAR1GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2007058601-A1 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176850-A1 | Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia | PSEN2, MAPT, PSEN1 | TAAR1 269/4885RIPK1 2912/4885GRM2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.